INVESTMENT AGREEMENT By and Between VIFOR (INTERNATIONAL) LTD. AND AKEBIA THERAPEUTICS, INC.Investment Agreement • August 8th, 2017 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTMENT AGREEMENT (this “Agreement”) is dated as of May 12, 2017, by and between Vifor (International) Ltd. (together with its permitted successors and assigns, the “Investor”), a corporation established in accordance with Swiss laws and registered in the commercial registry under CH-107.360.718, with its premises at Rechenstrasse 37, 9014 St. Gallen, Switzerland, and Akebia Therapeutics, Inc. (together with its permitted successors and assigns, the “Company”), a Delaware corporation, with its principal place of business at 245 First Street, Suite 1100, Cambridge, Massachusetts 02142.
LICENSE AGREEMENT BY AND BETWEEN AKEBIA THERAPEUTICS, INC. AND Vifor (INTERNATIONAL) LTD.License Agreement • August 8th, 2017 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into as of May 12, 2017 (the “Execution Date”) between Akebia Therapeutics, Inc., a company organized and existing under the laws of the State of Delaware, United States of America with its principal offices at 245 First Street, Cambridge, MA 02142 (“Akebia”), and Vifor (International) Ltd., a corporation established in accordance with Swiss laws and registered in the commercial registry under CH-107.360.718, with its premises at Rechenstrasse 37, 9014 St. Gallen, Switzerland (“Licensee”).
Collaboration and License Agreement By and Between Akebia Therapeutics, inc.Collaboration and License Agreement • August 8th, 2017 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
This Collaboration And License Agreement (this “Agreement”) is made and entered into as of April 25, 2017 (the “Effective Date”) between Akebia Therapeutics, Inc., a company organized and existing under the laws of the State of Delaware, United States of America with its principal offices at 245 First Street, Cambridge, MA 02142 (“Akebia”), and Otsuka Pharmaceutical Co. Ltd., a company organized and existing under the laws of Japan, having a registered office located at 2-9, Kanda Tsukasa-machi, Chiyoda-ku, Tokyo 101-8535, Japan (“Licensee”).
